Prof. Geoffrey Ginsburgi avalik loeng “The era of Personalized Medicine”.
12. Juunil 2014 kell 10:00-11:00 esineb EV Sotsiaalministeeriumis (Gonsiori 29, 15027 Tallinn) avaliku loenguga Duke ülikooli professor ja personaalse meditsiini eestkõneleja USA-s Prof. Geoffrey Ginsburg.
Prof. Geoffrey Ginsburg on 13.-14. juunil Tartus toimuva 14-nda Geenifoorumi üks peaesinejaid, kelle senine uurimistöö on keskendunud uute paradigmade väljatöötamisele genoomilise meditsiini rakendamiseks tavameditsiinis ja personaalse meditsiini integreerimiseks tervishoiusüsteemi.
Sotsiaalministeeriumis peab Prof. Ginsburg avaliku loengu: “The era of Personalized Medicine”, ning seda on oodatud kuulama kõik huvilised.
Director, Genomic Medicine, Duke Institute for Genome Sciences & Policy
Executive Director, Center for Personalized and Precision Medicine, Duke Medicine
Professor of Medicine and Pathology, Duke University Medical Center
Professor of Biomedical Engineering, Duke Pratt School of Engineering Dr. Ginsburg is the founding director for Genomic Medicine in the Duke Institute for Genome Sciences & Policy and the founding executive director of the Center for Personalized Medicine in the Duke University Health System. While at Duke, Dr. Ginsburg has pioneered translational genomics, initiating programs in genome enabled biomarker discovery, longitudinal registries with linked molecular and clinical data, biomarker-informed clinical trials, and the development of novel practice models and implementation research for the integration of genomic tools in heath care systems. With a strong commitment to interdisciplinary science he has led projects to develop predictive models for common complex diseases using high dimensional genomic data as well as collaborations with engineering groups to develop novel point of care sensors. He is an internationally recognized expert in genomics and personalized medicine with funding from NIH, DOD, Air Force, DARPA, the Gates Foundation, and industry. Prior to Duke he was at Millennium Pharmaceuticals Inc where he was vice president of Molecular and Personalized Medicine and responsible for developing pharmacogenomic and biomarker strategies for therapeutics.
He serves as an expert panel member for Genome Canada, as a member of the Board of External Experts for the NHLBI, as Co-Chair of the Institute of Medicine’s Roundtable on Genome-Based Research to Human Health, as a member of the advisory council for the National Center for Accelerating Translational Science, as co-Chair of the Cures Acceleration Network, as an Advisor to the Pharmacogenetics Research Network, and as a member of the World Economics Forum’s Global Agenda Council on Personalized and Precision Health Care.